**NEUROENDOCRINE DISEASE ORIENTED GROUP**

CHESAHE HOTEL, TORONTO, ON  
ROOM: ROSSETTI  
SATURDAY APRIL 28, 2018, 11:45 AM – 12:30 PM

CO-CHAIRS: DR. TIM ASMIS AND DR. SIMRON SINGH  
SENIOR INVESTIGATOR: DR. CHRIS O’CALLAGHAN

**CME Credits:**
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

**Learning Objectives:**

- To interpret and address, through clinical and translational research, the disease burden associated with gastroenteropancreatic neuroendocrine malignancies in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gastroenteropancreatic neuroendocrine malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to gastroenteropancreatic neuroendocrine malignancies.
- To interpret and apply new clinical trial methodologies in the field of clinical research in gastroenteropancreatic neuroendocrine malignancies.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 11:45 am | Setting Strategic Plan  
New Concepts in Development                                                                 | Dr. T. Asmis  
Dr. S. Singh |
| 12:00 pm | TEMPTATION STUDY (AGITG): Temozolomide and Pembrolizumab Together to Increase Immunogenicity of Advanced Pancreatic Neuroendocrine Tumours | Dr. R. Goodwin |
| 12:10 pm | A Phase II study of Avelumab In Addition to Radiotherapy in unresectable/metastatic, progressive Grade 2-3 Neuroendocrine Tumors | Dr. S. Myerhaug  
Dr. S. Singh |
| 12:20 pm | COMMNETS – Commonwealth Neuroendocrine Tumour Collaboration | Dr. S. Singh |
| 12:25 pm | Intergroup Task Force Update                                                                 | Dr. T. Asmis |
| 12:30 pm | Meeting Adjourned                                                                           |                        |